Research programme: KRAS protein modulators - PhoreMost Ltd
Latest Information Update: 04 Aug 2016
At a glance
- Originator University of Cambridge
- Developer Phoremost
- Class Small molecules
- Mechanism of Action KRAS protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer